Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

NewsVoir New Delhi [India] 3 Indraprastha Apollo Hospitals proudly announces the launch of its Heart Valve Clinic a dedicated ...

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation (EW)'s share ...

David Correa Allied Market Research + + 1 800-792-5285 email us here Visit us on social media: Facebook X LinkedIn YouTube ...